Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats.
Hydrolysis by endothelial lipases of triacylglycerol-rich lipoproteins of diabetic origin were compared to lipoproteins of non-diabetic origin. The plasma lipoprotein fraction of density < 1.006 g/ml, including chylomicrons and VLDL, were incubated in vitro with post-heparin plasma (PHP) lipases. The lipoproteins of diabetic origin were hydrolysed at a significantly slower rate than lipoproteins from normal rats by the lipoprotein lipase component of PHP. However, if rats were fasted for 16 h prior to lipoprotein recovery, no differences in rates of VLDL hydrolysis were observed. Slower hydrolysis of lipoproteins of diabetic origin reflected a decrease in the apolipoprotein CII/CIII ratio and other changes in the apolipoprotein profile. To assess whether diabetic rats were less able to clear triacylglycerol independent of changes in the nature of the lipoproteins, we monitored the clearance of chylomicron-like lipid emulsions in hepatectomized rats. In vivo, emulsion triacylglycerol hydrolysis was not slowed due to diabetes. However, control and diabetic rats, which had been fasted for 16 h, cleared triacylglycerol at about twice the rate of fed rats. Triacylglycerol secretion rates in diabetic and control rats were similar, whether fed or fasted. We conclude that in streptozocin diabetic rats, hypertriglyceridemia was not due to overproduction of chylomicron- or VLDL-triacylglycerol, nor to decreased endothelial lipase activities. Rather, in fed diabetic rats, the triacylglycerol-rich lipoproteins are poorer substrates for lipoprotein lipase. This may lead to slower formation of remnants which would exacerbate slow remnant removal. VLDL of diabetic origin were hydrolysed as efficiently as VLDL from control donors, suggesting that in the fed state the lipolytic defect may be specific for chylomicrons.
Mamo
J C
JC
Department of Physiology, University of Western Australia, Nedlands.
Hirano
T
T
Sainsbury
A
A
Fitzgerald
A K
AK
Redgrave
T G
TG
D000818:Animals; D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000302:isolation & purification; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism*; D004655:Emulsions / Q000302:isolation & purification; D005215:Fasting; D005227:Fatty Acids / Q000032:analysis; D006498:Hepatectomy; D015228:Hypertriglyceridemia / Q000150:complications / Q000378:metabolism*; D007328:Insulin / Q000097:blood; D008066:Lipolysis; D008079:Lipoproteins, VLDL / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
D001053:Apolipoproteins; D001786:Blood Glucose; D002914:Chylomicrons; D004655:Emulsions; D005227:Fatty Acids; D007328:Insulin; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol